Institutional shares held 46.5 Million
121K calls
33.2K puts
Total value of holdings $149M
$386K calls
$106K puts
Market Cap $104M
32,382,400 Shares Out.
Institutional ownership 143.73%
# of Institutions 145


Latest Institutional Activity in FDMT

Top Purchases

Q1 2025
Harbor Capital Advisors, Inc. Shares Held: 30.6K ($98.2K)
Q1 2025
Amalgamated Bank Shares Held: 1.74K ($5.58K)
Q4 2024
Millennium Management LLC Shares Held: 1.42M ($4.56M)
Q4 2024
Goldman Sachs Group Inc Shares Held: 4.27M ($13.7M)
Q4 2024
Jpmorgan Chase & CO Shares Held: 820K ($2.63M)

Top Sells

Q1 2025
Sg Americas Securities, LLC Shares Held: 22.9K ($73.4K)
Q1 2025
Rhumbline Advisers Shares Held: 70.8K ($227K)
Q1 2025
Assenagon Asset Management S.A. Shares Held: 651K ($2.09M)
Q1 2025
Gamma Investing LLC Shares Held: 8 ($25.7)
Q1 2025
Farther Finance Advisors, LLC Shares Held: 0 ($0)

About FDMT

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.


Insider Transactions at FDMT

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
38.3K Shares
From 2 Insiders
Exercise of conversion of derivative security 38.3K shares
Sell / Disposition
6.25M Shares
From 4 Insiders
Other acquisition or disposition 6.22M shares
Open market or private sale 38.3K shares

Track Institutional and Insider Activities on FDMT

Follow 4D Molecular Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells FDMT shares.

Notify only if

Insider Trading

Get notified when an 4 D Molecular Therapeutics, Inc. insider buys or sells FDMT shares.

Notify only if

News

Receive news related to 4D Molecular Therapeutics, Inc.

Track Activities on FDMT